Search the Newsreel

Tolu Minerals Limited (ASX:TOK) Share Price Falls as Investors Monitor Tolukuma Gold Project Progress

Autolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End

(RTTNews) - Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, announced financial results for the second quarter reflecting approximately 119% revenue growth from AUCATZYL product sales and a narrower net loss. Autolus Therapeutics develops T cell therapies and candidates for the treatment of cancer …

Assenagon Asset Management S.A. Boosts Holdings in Bristol Myers Squibb Company $BMY

[Gen-AI Analysis] Autoliv co-hosts Tech Day at Chery Auto

Autoliv and Chery Automobile Co., Ltd. co-hosted a Tech Day to discuss development trends, application scenarios, and future R&D collaboration in automotive safety technology. Autoliv showcased over 60 items during the event. The full article content is available for paid members, with a limited-time …

Annex Advisory Services LLC Acquires 14,829 Shares of Toll Brothers Inc. $TOL

Annex Advisory Services LLC increased its holdings in Toll Brothers Inc. by 32.4%, acquiring an additional 14,829 shares and bringing its total stake to 60,662 shares valued at approximately $9.99 million. Toll Brothers, a luxury homebuilder, surpassed quarterly earnings expectations with $2.72 EPS on …

How Investors May Respond To Toll Brothers (TOL) Doubling Down On Luxury Communities Amid Cautious Earnings Expectations

Toll Brothers (TOL) has been emphasizing luxury community development, including recent openings and final home opportunities across multiple states, with homes ranging from mid-$400,000s to over $3 million. This strategy comes as analysts are cautious about the company's upcoming earnings report on August 18, …

AstraZeneca held talks with Bristol-Myers through spring, summer - FT

AstraZeneca reportedly engaged in discussions with Bristol-Myers Squibb over the spring and summer regarding a potential acquisition. The talks were centered around AstraZeneca purchasing Bristol-Myers in a mostly stock-based deal at a premium.

Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AUTL) 2026-08-11

* Autolus Therapeutics (AUTL [https://seekingalpha.com/symbol/AUTL]) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. * The consensus EPS Estimate is -$0.19 [https://seekingalpha.com/symbol/AUTL/earnings/estimates] (-5.6% Y/Y) and the consensus Revenue Estimate is $40.15M (+92.1% Y/Y). * Over the last 1 year, …

Toll Brothers at Fortune Ridge Community Opens in Southeast, New York Intrado

Toll Brothers has announced the opening of its new luxury home community, Toll Brothers at Fortune Ridge, in Southeast, New York. Located about 60 miles north of Manhattan, the community offers single-family estates with modern architecture, extensive personalization options, and amenities including a clubhouse, …

Autolus Raises Year-End Outlook as Aucatzyl Sales Accelerate

Autolus' revenue from its CAR T-cell therapy Aucatzyl more than doubled in Q2 2026 compared to Q2 2025, reaching $45.7 million, leading the company to raise its full-year product revenue guidance to between $140 million and $150 million. The company is focusing on expanding …

Toll Brothers at Fortune Ridge Community Opens in Southeast, New York

Toll Brothers, Inc. SOUTHEAST, N.Y., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced its newest community, Toll Brothers at Fortune Ridge, is now open in Southeast, New York, approx. 60 miles north of …

Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS

Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum

Autolus Therapeutics plc reported better-than-expected Q2 results with a narrower loss per share and significantly higher revenue, exceeding analyst estimates. The company raised its full-year 2026 revenue guidance for AUCATZYL, indicating strong launch momentum driven by physician enthusiasm and expanding use. Improvements in gross …

Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings

Autolus Therapeutics (NASDAQ:AUTL) saw its shares rise by 13.3% after reporting stronger-than-expected quarterly earnings. The company posted a negative EPS of $0.15, beating estimates by $0.06, and revenue of $45.69 million, exceeding the $38.56 million forecast. Analyst sentiment remains largely positive, with a "Moderate …

Toll Brothers Announces Final Opportunity to Own a Luxury Home in the Bella Terra Collection at Tesoro Highlands in Valencia, California

Toll Brothers, Inc. announced the final opportunity to purchase a new luxury home in the Bella Terra Collection at Tesoro Highlands in Valencia, California. Only three homes remain, including a fully furnished model home. These homes offer spacious designs, resort-style amenities, and are priced …

Autolus Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary

Autolus Therapeutics PLC has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters and accessible through TradingView, provides a concise overview of the company's financial performance during this period. Readers can access the full report for …

Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors

Reports recently surfaced regarding a potential merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb, causing significant industry speculation. Although a senior source reportedly debunked these rumors, the prospect of such a large-scale merger between two strong performers raised questions about its strategic rationale …

Autolus Therapeutics' AUCATZYL Q2 Revenue Surges 119%; Boosts FY26 Outlook

(RTTNews) - Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, has announced its operational and financial results for the second quarter ended June 30, 2026. The company's marketed therapy, AUCATZYL (obecabtagene autoleucel; obe-cel), is a CD19-directed CAR-T therapy approved for adults with relapsed or …

Zacks Research Issues Negative Forecast for Autoliv Earnings

Zacks Research has lowered its Q3 2026 EPS forecast for Autoliv (NYSE:ALV) to $2.24 from $2.74, while the full-year consensus stands at $10.04. This comes after Autoliv narrowly missed EPS expectations in its latest quarter with $2.43 reported against an estimate of $2.46, despite …

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics reported significant financial and operational progress in Q2 2026, with AUCATZYL® net product revenue reaching $45.7 million, a 119% year-over-year increase, and full-year guidance raised to $140-$150 million. The company also strengthened its capital base with a $250 million credit facility and …

Autolus shares rise 3% on Q2 beat, raised revenue guidance

Autolus Therapeutics (NASDAQ:AUTL) reported a Q2 beat, with shares rising 3.19% pre-market. The company exceeded analyst expectations with a loss of -$0.15 per share and revenue of $45.7 million, a 119% increase YoY. Autolus also raised its full-year 2026 net product revenue guidance for …

Noida Toll Bridge Company Ltd is Rated Sell

Toll Brothers (TOL) Projected to Post Quarterly Earnings on Tuesday

Toll Brothers (TOL) is anticipated to release its Q3 2026 earnings after the market closes on Tuesday, August 18th, with analysts projecting $2.92 EPS on $2.618 billion in revenue. The company's previous quarter surpassed expectations, and analysts foresee $13 EPS for the current fiscal …

Autolus Therapeutics (AUTL) Earnings Date and Reports 2026 $AUTL

Tolu Minerals Shares Move Higher Today – Here’s Why

METTLER-TOLEDO INTERNATIONAL INC. : MORGAN STANLEY RAISES TARGET PRICE TO $1450 FROM $1275

Morgan Stanley has increased its target price for METTLER-TOLEDO INTERNATIONAL INC. (MTD) shares to $1450 from the previous $1275. This update reflects the investment bank's revised outlook on the company's stock.

News | Bristol Myers Squibb plans $2.3 billion Houston campus

Bristol Myers Squibb announced plans for a $2.3 billion, 600,000-square-foot campus in Houston's Generation Park, expected to create nearly 500 skilled jobs by 2030. This investment is part of a larger $40 billion commitment to U.S. operations, aiming to boost domestic manufacturing and reduce …

Is Schrödinger (SDGR) Undervalued Following Its Profit Turn And Bristol Myers Squibb Deal?

Bristol Myers Squibb lays out plan for $2.3B manufacturing facility in Houston

Bristol Myers Squibb has announced a $2.3 billion investment to build a manufacturing campus in Houston, significantly increasing its initial estimate of $1 billion. The facility, expected to employ nearly 500 people and be completed by 2030, will produce small molecules, biologics, and antibody-drug …

BMS Chooses Houston for $2.3B Manufacturing Facility

Bristol Myers Squibb (BMS) has selected Houston as the location for a new $2.3 billion multi-modal manufacturing campus. This facility, part of BMS's $40 billion U.S. investment, will support the production of various treatments including small molecules, biologics, and ADCs. The campus aims to …

What Investors Should Know About a Mettler-Toledo Director's Two Transactions This Past Week

A director at Mettler-Toledo International Inc. (MTD), Thomas P. Salice, recently sold 417 shares of the company, valued at approximately $600,651. This transaction was an exercise-and-sell of options, not a change in his long-term investment strategy, as he maintained significant indirect holdings. Mettler-Toledo has …

Pharma giant bets $2.3B on massive new Houston campus

Bristol Myers Squibb has chosen Houston for a new $2.3 billion manufacturing campus at Generation Park. This massive 600,000-square-foot facility is expected to create nearly 500 skilled jobs and approximately 2,000 indirect jobs during its construction phase. The investment is part of the company's …

A Mettler-Toledo Director Sold $600,000 in Stock. Here's What Investors Should Know

A director at Mettler-Toledo International Inc., Thomas P. Salice, sold 415 shares of common stock worth approximately $600,000 after exercising stock options. This transaction, occurring on August 3, was a same-day exercise and sale, where options acquired at a strike price of $397.95 were …

New Bristol Myers Squibb facility coming to Generation Park

Global biopharmaceutical company Bristol Myers Squibb is set to establish a new pharmaceutical manufacturing campus in the Houston area, specifically near Generation Park. FOX 26's Karys Belger reported on this development. The facility will mark a significant expansion for the company in the region.

Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know

Mettler-Toledo International's CFO, Shawn Vadala, sold 2,240 shares for approximately $3.2 million on August 3, 2026, by exercising stock options. This transaction followed a strong quarter for the company, which reported significant revenue growth and raised its full-year outlook. Despite the sale, Vadala retains …

What Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarter

Head of Process Analytics Gerry Keller reported a sale of 240 shares of Mettler-Toledo International Inc. (NYSE:MTD) on August 3, following a derivative exercise, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $342,514 Shares sold (direct) 240 Post-transaction …